GlassScriptPhysician profile
Brett A Penney
NPI 1164459798
$1,947.59
in general payments reported to CMS, 2019-2025
26 companies · $486 in 2025
The $486 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $280 · 2021: $71.20 · 2022: $160 · 2023: $420 · 2024: $387 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,292.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $350.70 | 2023-2024 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $303.65 | 2023-2025 | Gemtesa, Myfembree |
| Hologic Sales and Service, LLC | $223.19 | 2019-2025 | Fluent Fluid Management System, Novasure, Myosure Tissue Removal Device |
| Caldera Medical, INC | $201.67 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.17 | 2019-2025 | |
| Abbvie INC. | $116.50 | 2019-2022 | |
| Coopersurgical, INC. | $95.65 | 2020-2024 | Paragard T 380a, Paragard T 380a |
| Daiichi Sankyo INC. | $71.13 | 2024-2025 | Injectafer |
| Sage Therapeutics, LLC | $69.35 | 2025 | Zurzuvae |
| Exact Sciences Corporation | $57.25 | 2023-2024 | Cologuard Collection Kit |
| Coloplast Corp | $38.96 | 2024-2025 | |
| Exeltis, USA INC. | $30.96 | 2022-2024 | Slynd |
| Octapharma USA, INC. | $21.66 | 2025 | Fibryga |
| Solventum Corporation | $20.55 | 2025 | Prevena |
| C. R. Bard, INC. & Subsidiaries | $19.78 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $19.44 | 2025 | Quikclot |
| Pfizer INC. | $18.56 | 2025 | |
| Dysis Medical, INC. | $18.51 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.36 | 2025 | Qelbree |
| Sanofi Pasteur INC. | $16.95 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.88 | 2019 | |
| Organon LLC | $15.95 | 2025 | Nexplanon |
| Myovant Sciences INC. | $13.38 | 2021 | |
| Medtronic Vascular, INC. | $12.75 | 2019 | |
| Becton, Dickinson and Company | $12.64 | 2019 | |
| Merck Sharp & Dohme LLC | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Penney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.